Characterization of Salmonella enterica serovar Isangi from South Africa, 2020-2021.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Salmonella enterica*; Humans ; Serogroup ; South Africa/epidemiology ; Salmonella ; Anti-Bacterial Agents/pharmacology ; Drug Resistance, Multiple, Bacterial/genetics ; Microbial Sensitivity Tests

Background: We describe the genotypic characteristics and antimicrobial resistance (AMR) determinants of Salmonella enterica serovar Isangi (Salmonella Isangi) clinical isolates in South Africa from 2020 through 2021.
Methods: During the years 2020 to 2021, the Centre for Enteric Diseases of the National Institute for Communicable Diseases, a national reference centre in South Africa for human infections resulting from enteric bacterial pathogens, investigated a total of 3549 clinical isolates of Salmonella species. Whole genome sequencing (WGS) was performed using Illumina NextSeq Technology. WGS data was analyzed using Centre for Genomic Epidemiology-based tools and EnteroBase web-based platform. Genotypic relatedness and cluster analysis was investigated based on core-genome multilocus sequence typing.
Results: Forty-nine isolates were confirmed to be Salmonella Isangi, with most submitted from Gauteng Province (24/49, 49%). The most prevalent sequence type was ST335 (48/49, 98%), and the remaining 1 isolate was ST216. All ST335 isolates were genotypically multidrug-resistant (MDR), with resistance to fluoroquinolones, chloramphenicol, trimethoprim-sulfamethoxazole and tetracycline; the ST216 isolate was resistant only to aminoglycosides. All ST335 isolates carried ESBL genes, the most common being bla CTX-M-15 . Five clusters (consisting of isolates related within five allele differences) were detected, all being ST335.
Conclusions: Most Salmonella Isangi isolates in South Africa are MDR and ESBL-positive. Ongoing monitoring of the epidemiology and AMR profile of this serovar is important for public health and treatment guidelines.
(© 2023. The Author(s).)

Genome Res. 2018 Sep;28(9):1395-1404. (PMID: 30049790)
Pediatr Infect Dis J. 2006 Sep;25(9):843-4. (PMID: 16940846)
Curr Opin Investig Drugs. 2002 Sep;3(9):1284-90. (PMID: 12498001)
Lancet. 2012 Jun 30;379(9835):2489-2499. (PMID: 22587967)
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5515-20. (PMID: 27381390)
Diagn Microbiol Infect Dis. 2008 Sep;62(1):86-91. (PMID: 18513912)
J Med Microbiol. 2023 Jul;72(7):. (PMID: 37462464)
J Clin Microbiol. 2002 Dec;40(12):4679-84. (PMID: 12454172)
Foodborne Pathog Dis. 2019 Jul;16(7):504-512. (PMID: 31246502)
Front Microbiol. 2018 Mar 27;9:592. (PMID: 29636749)
PLoS One. 2020 Nov 12;15(11):e0241984. (PMID: 33180785)
BMC Microbiol. 2019 Jul 2;19(1):148. (PMID: 31266463)
Antimicrob Agents Chemother. 2004 Nov;48(11):4263-70. (PMID: 15504851)
Saudi J Biol Sci. 2015 Jan;22(1):90-101. (PMID: 25561890)
Antimicrob Agents Chemother. 2019 Oct 22;63(11):. (PMID: 31427293)

Keywords: Africa; ESBL; Isangi; Salmonella enterica; Serovar Isangi; South Africa

0 (Anti-Bacterial Agents)

Salmonella enterica subsp. enterica

Date Created: 20231114 Date Completed: 20231115 Latest Revision: 20231116

20240829

PMC10644633

10.1186/s12879-023-08786-9

37957562